Activity in the field of Cell and Gene Therapy (CAGT) has been steadily increasing as the techniques are refined, and patient selection and monitoring are standardized. This white paper builds on the first paper in the CAGT Hot Buttons series, “Starting the CAR: An Introduction To Autologous CAR-T Therapy”. Here, we discuss frequently encountered medical hazards of the most widely available autologous Chimeric Antigen Receptor T-cell (CAR-T) therapies in the B cell hematologic malignancy patient population. These complications are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cardiovascular toxicity, tumor lysis syndrome, infections, hypogammaglobulinemia and cytopenia. We outline considerations for the management of these toxicities and we present some considerations from a clinical trial perspective.